Clinical Trials Logo

Hyperlipoproteinemia Type II clinical trials

View clinical trials related to Hyperlipoproteinemia Type II.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT04759534 Active, not recruiting - Clinical trials for Heterozygous Familial Hypercholesterolemia

Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia

Start date: September 10, 2020
Phase: Phase 3
Study type: Interventional

This study plans to enroll several patients with heterozygous familial hypercholesterolemia, randomly assigned to different dose groups, and randomly receiving subcutaneous injection of IBI306150 mg or placebo every two weeks: or subcutaneous injection of IBI306 450mg every four weeks (n=49) or placebo (n=25) treatment, treatment lasted for 12 weeks. During randomization, the LDL-C level (<4.8mmol/L or ≥4.8mmol/L) observed during the screening period visit (VI), and whether ezetimibe was used for stratification. After 12 weeks, each group entered the 12-week open-period treatment, in which subjects in the IBI306 group continued to receive IBI306 treatment, and subjects in the placebo group stopped using placebo and received IBI306 treatment. The exploratory endpoint is the population pharmacokinetic characteristics of IBI306 in Chinese heterozygous familial hypercholesterolemia population.

NCT ID: NCT04681170 Active, not recruiting - Clinical trials for Homozygous Familial Hypercholesterolaemia (HoFH)

Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Start date: December 14, 2020
Phase: Phase 3
Study type: Interventional

This is a single arm, open label, multi centre phase III study to evaluate the efficacy and long term safety of lomitapide in paediatric patients with HoFH receiving stable LLT (including LA, when applicable) comprising of the following phases: - Screening Period (starting at Week 12, i.e. ≤12 weeks prior to Baseline for up to 6 weeks) - Stratified Enrolment and Start of Run in Period (starting at minimum at Week 6, i.e., 6 weeks prior to Baseline for a minimum of 6 weeks): - Efficacy Phase (starting at Baseline, i.e. Day [D] 0 for 24 weeks±3 days - Safety Phase (starting at Week 24±3 days for 80±1 weeks)

NCT ID: NCT04659863 Active, not recruiting - Clinical trials for Familial Hypercholesterolemia - Homozygous

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

ORION-13
Start date: February 16, 2021
Phase: Phase 3
Study type: Interventional

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C).

NCT ID: NCT04652726 Active, not recruiting - Clinical trials for Familial Hypercholesterolemia - Heterozygous

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

ORION-16
Start date: January 27, 2021
Phase: Phase 3
Study type: Interventional

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C).

NCT ID: NCT04080050 Active, not recruiting - Clinical trials for Homozygous Familial Hypercholesterolemia (HoFH)

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501

Start date: September 30, 2019
Phase:
Study type: Observational

This long-term observational study is designed to follow subjects who, during another Clinical Study, received gene therapy treatment used to treat their Homozygous Familial Hypercholesterolemia (HoFH) disease. This study is intended to follow those subjects for up to 5 years since they received treatment to look for any long-term safety concerns. There is no investigational drug or therapy provided as part of this study.

NCT ID: NCT03900169 Active, not recruiting - Clinical trials for Familial Hypercholesterolemia

Familial Hypercolerstremia as Risk Factor in Stemi Patient Who Underwent Ppci

Start date: November 1, 2020
Phase:
Study type: Observational

Famulial hypercolerstremia as risk factor

NCT ID: NCT03832985 Active, not recruiting - Clinical trials for Familial Hypercholesterolemia

Pediatric Reporting of Adult-Onset Genomic Results

Start date: November 25, 2020
Phase: Early Phase 1
Study type: Interventional

The Investigators will conduct a longitudinal, mixed-methods cohort study to assess primary and secondary psychosocial outcomes among 705 MyCode pediatric participants and their parents, and health behaviors of parents whose children receive an adult- or pediatric-onset genomic result. Data will be gathered via quantitative surveys using validated measures of distress, family functioning, quality of life, body image, perceived cancer/heart disease risk, genetic counseling satisfaction, genomics knowledge, and adjustment to genetic information; qualitative interviews with adolescents and parents; and electronic health records review of parents' cascade testing uptake and initiation of risk reduction behaviors. The investigators will also conduct empirical and theoretical legal research to examine the loss of chance doctrine and its applicability to genomic research.

NCT ID: NCT03135184 Active, not recruiting - Clinical trials for Homozygous Familial Hypercholesterolemia

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Start date: January 26, 2018
Phase: N/A
Study type: Interventional

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System